- Home
- ARGX vs WIT Comparison
ARGX vs WIT Comparison
Compare ARGX & WIT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ARGX
- WIT
- Stock Information
- Founded
- ARGX 2008
- WIT 1945
- Country
- ARGX Netherlands
- WIT India
- Employees
- ARGX N/A
- WIT N/A
- Industry
- ARGX Biotechnology: Biological Products (No Diagnostic Substances)
- WIT EDP Services
- Sector
- ARGX Health Care
- WIT Technology
- Exchange
- ARGX Nasdaq
- WIT Nasdaq
- Market Cap
- ARGX 33.0B
- WIT 29.9B
- IPO Year
- ARGX 2017
- WIT N/A
- Fundamental
- Price
- ARGX $545.41
- WIT $3.10
- Analyst Decision
- ARGX Strong Buy
- WIT Hold
- Analyst Count
- ARGX 17
- WIT 1
- Target Price
- ARGX $730.07
- WIT N/A
- AVG Volume (30 Days)
- ARGX 389.0K
- WIT 4.7M
- Earning Date
- ARGX 07-24-2025
- WIT 07-18-2025
- Dividend Yield
- ARGX N/A
- WIT 2.00%
- EPS Growth
- ARGX N/A
- WIT 20.27
- EPS
- ARGX 15.94
- WIT 0.15
- Revenue
- ARGX $2,643,062,000.00
- WIT $10,426,195,411.00
- Revenue This Year
- ARGX $61.64
- WIT $3.12
- Revenue Next Year
- ARGX $32.00
- WIT $5.33
- P/E Ratio
- ARGX $31.61
- WIT $21.27
- Revenue Growth
- ARGX 82.13
- WIT N/A
- 52 Week Low
- ARGX $429.27
- WIT $2.63
- 52 Week High
- ARGX $678.21
- WIT $3.79
- Technical
- Relative Strength Index (RSI)
- ARGX 41.20
- WIT 61.01
- Support Level
- ARGX $510.06
- WIT $2.96
- Resistance Level
- ARGX $563.36
- WIT $3.10
- Average True Range (ATR)
- ARGX 15.45
- WIT 0.04
- MACD
- ARGX -0.61
- WIT 0.00
- Stochastic Oscillator
- ARGX 44.37
- WIT 85.71
About ARGX argenx SE
Argenx is a Dutch biopharmaceutical company focused on developing antibody-based therapies for rare autoimmune diseases. The company's lead product, Vyvgart (efgartigimod), was approved by the FDA in December 2021 for the treatment of generalized myasthenia gravis (gMG). In 2022, Argenx also received FDA approval for Vyvgart Hytrulo, a subcutaneous formulation of Vyvgart, offering a more convenient option compared with Vyvgart's intravenous administration. In 2024, the FDA approved Vyvgart Hytrulo for Chronic Inflammatory Demyelinating Polyneuropathy, a rare immune-mediated neuromuscular disorder of the peripheral nervous system. Argenx is focused on innovation and developing its pipeline for treatments such as primary immune thrombocytopenia, thyroid eye disease, and Sjogren's Disease.
About WIT Wipro Limited
Wipro is a leading global IT services provider, with over 234,000 employees. Based in Bengaluru, this India IT services firm leverages its offshore outsourcing model to derive a significant portion of its revenue from North America. The company offers traditional IT services offerings: consulting, managed services, and cloud infrastructure services as well as business process outsourcing as a service.